Nasal Septum Perforation in a Bevacizumab-Treated Patient with Metastatic Breast Cancer
Open Access
- 1 November 2006
- journal article
- case report
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 11 (10) , 1070-1071
Abstract
The Oncologist is a journal devoted to medical and practice issues for surgical, radiation, and medical oncologists.Keywords
This publication has 8 references indexed in Scilit:
- Bevacizumab-Induced Nasal Septum PerforationThe Oncologist, 2006
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumabJournal of Surgical Oncology, 2005
- High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200Journal of Clinical Oncology, 2005
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Clinical Experience with Angiogenesis Signaling Inhibitors: Focus on Vascular Endothelial Growth Factor (VEGF) BlockersCancer Control, 2002